Comparative Pharmacology
Head-to-head clinical analysis: MYFED versus PSEUDO 12.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MYFED versus PSEUDO 12.
MYFED vs PSEUDO-12
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Pseudoephedrine is a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the respiratory tract mucosa, causing vasoconstriction and reducing nasal congestion.
Decongestant; acts on alpha-adrenergic receptors in the nasal mucosa to produce vasoconstriction, reducing edema and nasal congestion.
500 mg orally twice daily with meals.
60 mg orally every 4 to 6 hours as needed; maximum 240 mg per day.
None Documented
None Documented
3-5 hours in adults with normal renal function; prolonged to 12-24 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life: 4-6 hours (adults); 6-8 hours (children); prolonged in renal impairment (up to 20 hours in severe disease).
Primarily renal (85-90% as unchanged drug) via glomerular filtration and tubular secretion; minor biliary/fecal excretion (5-10%).
Renal: 70-90% as unchanged drug; biliary/fecal: <10%
Category C
Category C
Decongestant
Decongestant